10-Q · June 11, 2026
Nutriband Inc. reported a revenue decrease to $433,399 in Q4 2026 from $667,432 in Q4 2025, reflecting ongoing challenges with operational stability. Gross margins showed a slight deterioration after addressing higher…
Earnings analysis · 10-Q
NTRB earnings analysis
Filed September 4, 2026 · Our reading of the company's report
The latest report
The supplied 10-Q text does not include the financial statements or MD&A needed to assess revenue, margins, EPS, balance-sheet changes, cash flow, or segment trends; those metrics are therefore unavailable.…
Read full summary
The supplied 10-Q text does not include the financial statements or MD&A needed to assess revenue, margins, EPS, balance-sheet changes, cash flow, or segment trends; those metrics are therefore unavailable. Qualitatively, the filing is negative: disclosure controls remain ineffective, material weaknesses persist, and the company has 1 lead product in development but 0 products marketable in the United States. Litigation exposure includes claims exceeding $500,000 and a $100,000 unresolved settlement proposal, while geopolitical and capital-market risks could further impair liquidity.
Gross and operating margin
How much of each revenue dollar the business keeps.
One point per quarterly or annual filing. Both margins are shares of that report's revenue.
How we read each report
Our analysis across the last few reports.
Our model's reading of each filing, not the share price or the market's reaction. Annual and quarterly reports each occupy one position.
What stood out
-
Material control weaknesses remain
The company disclosed that its disclosure controls and procedures were not effective under Exchange Act Rule 13a-15. Management identified material weaknesses involving segregation of duties, qualified accounting personnel, and reliance on third-party consultants, while also reporting additional monitoring controls and detailed reviews of revenue, receivables, and payables.
-
Litigation exposure is significant
The company is defending a lawsuit seeking more than $500,000 in damages plus punitive damages, while its counterclaims seek $1,000,000 for each of 2 claims. The case is in discovery, and a $100,000 settlement offer made in early 2024 remains unanswered.
-
No U.S.-marketed product
The filing states that the company has not completed development of its 1 lead product, an abuse-deterrent fentanyl transdermal system, and has 0 products it can market in the United States. It therefore cannot predict when or whether it will operate profitably.
-
Geopolitical uncertainty adds pressure
The company identified geopolitical and economic uncertainty, including the United States being involved in a war with Iran, as potential threats to tariffs, health-care and medical-product markets, margins, liquidity, and access to additional capital.
What to watch
-
Ineffective disclosure controls
Disclosure controls were deemed ineffective as of the period end, with material weaknesses tied to the absence of segregation of duties, a lack of qualified accounting personnel, and reliance on third-party consultants. This raises the risk of reporting errors despite remediation efforts.
-
Pending legal claims
The company faces a lawsuit seeking more than $500,000 plus punitive damages, while legal fees are also sought by the plaintiff's counsel. The matter remains in discovery, and the company has not responded to a $100,000 settlement proposal made in early 2024.
-
Regulatory and funding dependency
The company has 1 lead product still in development and 0 products marketable in the United States. Delays in clinical trials or FDA review could extend losses and negative cash flow and prevent the company from achieving profitability.
Management's outlook
No quantitative revenue or EPS outlook is included in the supplied 10-Q text; outlook may be deferred to the earnings release or call.
Earlier filings 4
10-K · May 18, 2026
Nutriband Inc. (NTRB) reported ongoing financial challenges with continuing losses and negative profit margins throughout the fiscal year ended January 31, 2026. The company is also facing significant market pressures…
10-K · April 29, 2026
Nutriband Inc. (NTRB) disclosed a challenging financial outlook in its 10-K, with the company experiencing substantial losses and negative profit margins in recent quarters. The filing highlights the impact of…
10-Q · December 11, 2025
Nutriband reported Q3 revenue of $346,058, a 46.4% decline versus Q3 2024 revenue of $645,796 and a sharp sequential decline from the prior quarter. Gross margin fell to 19.8% while operating loss widened to $3,880,336…
This is our reading of a public filing, not the filing itself. Analysis can contain errors; check the source document for full context.